The United States Patent & Trademark Office has granted a patent covering the company’s technology for tolerogenic immune therapy.
This technology forms the basis of the new therapies developed by Idogen to prevent the immune system from disabling the standard treatment of hemophilia, as well as causing rejection of transplanted organs. Patents in the same patent family have previously been granted in Japan and in Europe. The new patent in USA will provide Idogen’s immune therapy technology with important and broad protection in a key market and significantly strengthens the company’s patent portfolio.
The United States Patent & Trademark Office issued in March 2017 a “Notice of Allowance” and has now formally granted a patent, US 9,839,674, for Idogen’s Patent Application No. 14/553,098. The patent belongs to Idogen’s second patent family and covers the use of the company´s immune technology for treatment of autoimmune diseases and tolerance of transplanted organs. The patent term extends to December 20, 2031. A related patent application is pending in Canada. The granted patent complements the Japanese and European granted patents in this family and an earlier European patent in Idogen’s first patent family, granted in December 2013.
“The patent now granted providesstrong intellectual property protection in the world’s largest pharmaceutical market, thereby significantly increasing the commercial potential of our innovative tolerogenic immunotherapies”, Idogen´s CEO Lars Hedbys comments.
